SLCO1B1基因T521C多态性对氟伐他汀药代动力学、药效学和药物不良反应影响的系统评价

Systematic review of SLCO1B1 gene T521C polymorphism on fluvastatin in vivo pharmacokinetics/pharmacodynamics/adverse drug reactions

目的研究SLCO1B1基因T521C位点多态性与氟伐他汀药物的药代动力学、药效学和药物不良反应的相关性。方法本文采用计算机检索Cochrane Library、Pub Med、EMBase、Webof Science、中国知网和万方数据库,截至2017年12月。收集有关SLCO1B1基因多态性对氟伐他汀影响的研究。筛选文献并对最终纳入的6篇文献进行质量评价和系统综述。结果 SLCO1B1基因T521C位点多态性对服用氟伐他汀后的低密度脂蛋白浓度和总胆固醇降低有显著影响,对氟伐他汀的体内药代动力学过程没有显著影响,且没有证据证明该位点与氟伐他汀导致肌病的药物不良反应有相关性。结论 SLCO1B1基因T521C位点的多态性显著影响氟伐他汀的药效学,与氟伐他汀的药代动力学及药物不良反应的发生无关。

Objective To study the association between the SLCO1B1 gene T521C polymorphism and the pharmacokinetics,pharmacodynamics and adverse reactions of fluvastatin. Methods A computer-based search of the Cochrane Library,Pub Med,EMBase,Web of Science,CNKI and Wanfang databases was conducted to collect literature on the impact of SLCO1B1 gene polymorphism on fluvastatin. The literature was screened,and quality evaluation and systematical review were conducted for the 6 finally enrolled literature. Results SLCO1B1 gene T521C polymorphism significantly affects the drug efficacy of decreasing low-density lipoprotein and total cholesterol after taking fluvastatin,yet it has no significant effect on the pharmacokinetics of fluvastatin in vivo. There is no evidence that this site is associated with adverse reactions of myopathy caused by fluvastatin. Conclusion SLCO1B1 gene T521C polymorphism has significant influence on the pharmacodynamics of fluvastatin,but not related to the pharmacokinetics of fluvastatin and the occurrence of adverse drug reactions.